Abstract:Purpose: Post-stroke (PS) cognitive impairment (CI) is frequent and its devastating functional and vital consequences are well known. Despite recent guidelines, they are still largely neglected. A large number of recent studies have re-examined the epidemiology, diagnosis, imaging determinants and management of PSCI. The aim of this update is to determine whether these new data answer the questions that are essential to reducing PSCI, the unmet needs, and steps still to be taken. Methods: Literature review of stroke unit-era studies examining key steps in the management of PSCI: epidemiology and risk factors, diagnosis (cognitive profile and assessments), imaging determinants (quantitative measures, voxelwise localization, the disconnectome and associated Alzheimer's disease [AD]) and treatment (secondary prevention, symptomatic drugs, rehabilitation and noninvasive brain stimulation) of PSCI. Findings: (1) the prevalence of PSCI of approximately 50% is probably underestimated; (2) the sensitivity of screening tests should be improved to detect mild PSCI; (3) comprehensive assessment is now well-defined and should include apathy; (4) easily available factors can identify patients at high risk of PSCI; (5) key imaging determinants are the location and volume of the lesion and the resulting disconnection, associated AD and brain atrophy; WMH, ePVS, microhemorrhages, hemosiderosis, and cortical microinfarcts may contribute to cognitive impairment but are more likely to be markers of brain vulnerability or associated AD that reduce PS recovery; (6) remote and online assessment is a promising approach for selected patients; (7) secondary stroke prevention has not been proven to prevent PSCI; (8) symptomatic drugs are ineffective in treating PSCI and apathy; (9) in addition to cognitive rehabilitation, the benefits of training platforms and computerized training are yet to be documented; (10) the results and the magnitude of improvement of noninvasive brain stimulation, while very promising, need to be substantiated by large, high-quality, sham-controlled RCTs. Discussion and conclusion: These major advances pave the way for the reduction of PSCI. They include (1) the development of more sensitive screening tests applicable to all patients and (2) online remote assessment; crossvalidation of (3) clinical and (4) imaging factors to (5) identify patients at risk, as well as (6) factors that prompt a search for associated AD; (7) the inclusion of cognitive outcome as a secondary endpoint in acute and secondary stroke prevention trials; and (8) the validation of the benefit of noninvasive brain stimulation through high-quality, randomized, sham-controlled trials. Many of these objectives can be rapidly and easily attained.

Development and validation of domain-specific clinical prediction models of post-stroke cognitive impairment

Validating a Predictive Model of Acute Advanced Imaging Biomarkers in Ischemic Stroke

Prediction of Poststroke Depression Based on the Outcomes of Machine Learning Algorithms

Predictors of Cognitive Impairment after Stroke: A Prospective Stroke Cohort Study.

Prediction-Driven Decision Support for Patients With Mild Stroke: A Model Based on Machine Learning Algorithms

Predicting post-stroke cognitive impairment using electronic health record data

Predicting Poststroke Cognitive Impairment after Acute Ischemic Stroke Based on Admission Characteristics

Machine learning in the prediction of post-stroke cognitive impairment: a systematic review and meta-analysis

The Prognostic Value of Domain-Specific Cognitive Abilities Assessed by Chinese Version of Oxford Cognitive Screen on Determining ADLs Recovery in Patients with Post-Stroke Cognitive Impairment

Evaluation of the Mini-Mental State Examination and the Montreal Cognitive Assessment for Predicting Post-stroke Cognitive Impairment During the Acute Phase in Chinese Minor Stroke Patients

Predictors of Cognitive Functions After Stroke Assessed Using the Wechsler Adult Intelligence Scale: A Retrospective Study

Development and Validation of a Clinical Model (DREAM-LDL) for Post-Stroke Cognitive Impairment at 6 Months.

Post-stroke cognitive impairment remains highly prevalent and disabling despite state-of-the-art stroke treatment.

Specific Within-Domain Cognitive Impairments Predict Depression Severity Six-Months After Stroke

Improving diagnostic accuracy of the Montreal Cognitive Assessment to identify post-stroke cognitive impairment

Establishment and evaluation of a clinical prediction model for cognitive impairment in patients with cerebral small vessel disease

Development and validation of an interpretable machine learning model—Predicting mild cognitive impairment in a high-risk stroke population

Diagnostic Accuracy of Cognitive Screening Tools under Different Neuropsychological Definitions for Poststroke Cognitive Impairment.

Predictors of post stroke cognitive impairment: VITATOPS cognition substudy

Are we ready to cure post-stroke cognitive impairment? Many key prerequisites can be achieved quickly and easily

Short-term Montreal Cognitive Assessment predicts functional outcome after endovascular therapy